Accueil Ernstrade Bourse Actualite Stock


Exchanges: Frankfurt

The Group's principal activity is the research and development of new anticancer drugs. The Group's lead product - satraplatin - is currently in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer following successful completion of a Special Protocol Assessment by the U.S. FDA and receipt of a Scientific Advice letter from the European central regulatory authority, EMEA. Other anticancer programs include: a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and a small molecule broad-spectrum cell cycle inhibitors program, currently in pre-clinical development. The Group also has a number of drug discovery programs that leverage its expertise in kinase inhibitors. The Group has a multi-year alliance with ALTANA Pharma AG working with the ALTANA Research Institute in the U.S., which provides it with revenues through mid-2007.


Copyright   2009